1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

@article{Bronowicki20111195BA,
  title={1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION},
  author={J. Bronowicki and S. Pol and P. Thuluvath and D. Larrey and C. Martorell and V. Rustgi and D. W. Morris and Z. Younes and M. Fried and M. Bourli{\'e}re and C. H{\'e}zode and Omar I. Massoud and G. Abrams and V. Ratziu and A. Thiry and C. Llamoso and E. Hughes and R. Hindes},
  journal={Journal of Hepatology},
  year={2011},
  volume={54}
}
3. PR plus BOC for 44 weeks (BOC/PR48). Primary endpoint was SVR 24 wks post-therapy (Roche TaqMan LLD = 9.3 IU/mL). Results: SVR was numerically higher in patients with G1a (66–73%) compared to G1b (59–64%) in the BOC arms of both studies. Similarly, the number of patients with RAVs was higher with G1a infection and the rate of detectable RAVs in all patients for whom RAV testing was performed was higher in G1a infected subjects in both studies (Table). Conclusions: BOC/PR therapy is… Expand
19 Citations
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
  • 103
  • PDF
...
1
2
...